The global medical community is celebrating a historic victory as the U.S. Food and Drug Administration (FDA) has officially approved bepirovirsen by GlaxoSmithKline (GSK), the first-ever drug to offer a “functional cure” for millions of people living with Chronic Hepatitis B (CHB). Phase 3 clinical trial results published in the New England Journal of Medicine confirmed that the treatment successfully suppresses the virus and clears viral proteins to undetectable levels, allowing the patient’s own immune system to control the infection without permanent daily medication. Healthcare experts hail this as a major milestone that could drastically reduce global liver cancer rates.
About the Author
